DAVID CASTILLEJOS, M.D.
Medical Practice at 4 Ave, Chula Vista, CA
License number
California A44482
Category
Medical Practice
Type
Ophthalmology
Address
Address
480 4Th Ave STE 412, Chula Vista, CA 91910
Phone
(619) 422-1471
(619) 422-0450 (Fax)
(619) 422-0450 (Fax)
Organization information
See more information about DAVID CASTILLEJOS at bizstanding.comCastillejos Eye Institute - David Castillejos MD
480 4 Ave STE 412, Chula Vista, CA 91910
Categories:
General Surgeons, Laser Vision Correction, Ophthalmology Physicians & Surgeons, ...
Site:
Phone:
(619) 422-1471 (Phone)
Professional information
Agents For Intravitreal Administration To Treat Or Prevent Disorders Of The Eye
US Patent:
6462071, Oct 8, 2002
Filed:
Mar 2, 2000
Appl. No.:
09/517798
Inventors:
David Castillejos - Chula Vista CA
Assignee:
Vitreo-Retinal Technologies, Inc. - Irvine CA
International Classification:
A61K 3140
US Classification:
514413, 514588, 514912
Abstract:
Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e. g. , hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e. g. , adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Agents For Corneal Or Intrastromal Administration To Treat Or Prevent Disorders Of The Eye
US Patent:
7977385, Jul 12, 2011
Filed:
Mar 14, 2003
Appl. No.:
10/389226
Inventors:
Vicken H. Karageozian - Laguna Beach CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
Gabriel Arthuro Carpio Aragon - Tijuana, MX
Jose Luis Gutierres Floress - Tijuana, MX
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
Gabriel Arthuro Carpio Aragon - Tijuana, MX
Jose Luis Gutierres Floress - Tijuana, MX
Assignee:
Numoda Biotechnologies, Inc. - Philadelphia PA
International Classification:
A61K 31/17
US Classification:
514588, 514912
Abstract:
Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e. g. , hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e. g. , adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing nonenzymatic dissolution of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Agents For Intravitreal Administration To Treat Or Prevent Disorders Of The Eye
US Patent:
7008960, Mar 7, 2006
Filed:
Aug 9, 2002
Appl. No.:
10/215680
Inventors:
David Castillejos - Chula Vista CA, US
Assignee:
Vitreo-Retinal Technologies, Inc. - Irvine CA
International Classification:
A61K 31/40
US Classification:
514413, 514588, 514912
Abstract:
Methods and preparatons for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e. g. , hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e. g. , adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Treatment Of Ophthalmic Disorders Using Urea And Urea Derivatives
US Patent:
2007010, May 10, 2007
Filed:
Oct 23, 2006
Appl. No.:
11/585400
Inventors:
Vicken Karageozian - Laguna Beach CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
Assignee:
Vitreo-Retinal Technologies, Inc. - Irvine CA
International Classification:
A61K 31/343, A61K 31/17
US Classification:
514469000, 514580000, 514585000, 514595000
Abstract:
Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.
Agents For Intravitreal Administration To Treat Or Prevent Disorders Of The Eye
US Patent:
2005013, Jun 23, 2005
Filed:
Feb 17, 2005
Appl. No.:
11/061804
Inventors:
David Castillejos - Chula Vista CA, US
International Classification:
A61K038/00, A61K031/60, A61K031/415, A61K031/17
US Classification:
514002000, 514575000, 514588000, 514580000, 514165000, 514406000, 514570000
Abstract:
Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Treatment Of Ophthalmic Disorders Using Urea And Urea Derivatives
US Patent:
2003019, Oct 23, 2003
Filed:
Feb 13, 2003
Appl. No.:
10/367614
Inventors:
Vicken Karageozian - Laguna Beach CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
David Castillejos - Chula Vista CA, US
John Park - Santa Ana CA, US
Assignee:
Vitreo-Retinal Technologies, Inc. - Irvine CA
International Classification:
A61K031/343, A61K031/17, A61K031/155
US Classification:
514/468000, 514/580000, 514/588000, 514/595000, 514/634000
Abstract:
Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.